1. TYRA will present at major healthcare investor conferences. 2. Fireside chat scheduled for May 13, 2025, in Las Vegas. 3. TYRA-300 is a lead candidate in Phase 2 studies. 4. Additional investigational drugs include TYRA-200 and TYRA-430. 5. TYRA focuses on precision medicines targeting FGFR biology.
Investor engagement signals confidence and stability, similar to other biotech firms at conferences that often attract investor interest and may drive stock prices positively.
The article reflects significant investor engagement which can lead to price movements. As TYRA presents key data in multiple high-profile conferences, it will capture the attention of investors, potentially boosting stock demand.
Immediate investor interest may result in short-term stock price fluctuations around conference events.
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences:
A live and archived webcast of the fireside chat will be available via the For Investors page on the Investor section of the TYRA website.
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions.
The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is expected to be evaluated in three Phase 2 studies: SURF302 for IR NMIBC, BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial cancer.
TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.
Contact: Amy Conrad [email protected]
SOURCE Tyra Biosciences